Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1920 ARTÍCULOS , VIENDO DEL 1651 AL 1665

[Differentiation Between Alzheimer̓s Disease and Old Age Depression: Overview and Conception of a Questionnaire for Relatives]

Peichel S, Quante A.

Fortschr Neurol Psychiatr. 2024 May;92(5):186-193. doi: 10.1055/a-2202-9622. Epub 2023 Dec 19.

Advancements in investigating the role of cerebral small vein loss in Alzheimer's disease-related pathological changes

Hu Z, Li Z, Shi Y, Liu S, Shen Y, Hu F, Li Q, Liu X, Gou X, Chen Z, Yang D.

Neurol Sci. 2024 May;45(5):1875-1883. doi: 10.1007/s10072-023-07208-7. Epub 2023 Dec 22.

2D nanostructures: Potential in diagnosis and treatment of Alzheimer's disease

Tufail S, Sherwani MA, Shamim Z, Abdullah, Goh KW, Alomary MN, Ansari MA, Almosa AA, Ming LC, Abdullah ADI, Khan FB, Menhali AA, Mirza S, Ayoub MA.

Biomed Pharmacother. 2024 Jan;170:116070. doi: 10.1016/j.biopha.2023.116070. Epub 2023 Dec 31.

Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities

Hardy J, Schott JM.

Neurology. 2024 Feb 13;102(3):e208096. doi: 10.1212/WNL.0000000000208096. Epub 2023 Dec 28.

Deep learning applications in vascular dementia using neuroimaging

Dong C, Hayashi S.

Curr Opin Psychiatry. 2024 Mar 1;37(2):101-106. doi: 10.1097/YCO.0000000000000920. Epub 2023 Dec 20.

Methodologies for assessing morphosyntactic ability in people with Alzheimer's disease

Varlokosta S, Fragkopoulou K, Arfani D, Manouilidou C.

Int J Lang Commun Disord. 2024 Jan-Feb;59(1):38-57. doi: 10.1111/1460-6984.12862. Epub 2023 Feb 25.

Speech changes in old age: Methodological considerations for speech-based discrimination of healthy ageing and Alzheimer's disease

Ivanova O, Martínez-Nicolás I, Meilán JJG.

Int J Lang Commun Disord. 2024 Jan-Feb;59(1):13-37. doi: 10.1111/1460-6984.12888. Epub 2023 May 4.

The risk of dementia or cognitive impairment in patients with cataracts: a systematic review and meta-analysis

Wang L, Sang B, Zheng Z.

Aging Ment Health. 2024 Jan-Feb;28(1):11-22. doi: 10.1080/13607863.2023.2226616. Epub 2023 Jul 7.

Clinical characteristics of early-onset versus late-onset Alzheimer's disease: a systematic review and meta-analysis

Seath P, Macedo-Orrego LE, Velayudhan L.

Int Psychogeriatr. 2024 Dec;36(12):1093-1109. doi: 10.1017/S1041610223000509. Epub 2023 Jul 11.

Cognitive prescriptions for reducing dementia risk factors among Black/African Americans: feasibility, acceptability, and preliminary efficacy

Fazeli PL, Hopkins C, Vance DE, Wadley V, Li P, Turan B, Wang DH, Bowen PG, Clay OJ.

Ethn Health. 2024 Jan;29(1):1-24. doi: 10.1080/13557858.2023.2231669. Epub 2023 Jul 18.

Sex and gender differences in risk scores for dementia and Alzheimer's disease among cisgender, transgender, and non-binary adults

Brady B, Zheng L, Kootar S, Anstey KJ.

Alzheimers Dement. 2024 Jan;20(1):5-15. doi: 10.1002/alz.13317. Epub 2023 Jul 26.

Senile plaque-associated transactive response DNA-binding protein 43 in Alzheimer's disease: A case report spanning 16 years of memory loss

Carlos AF, Koga S, Graff-Radford NR, Baker MC, Rademakers R, Ross OA, Dickson DW, Josephs KA.

Neuropathology. 2024 Apr;44(2):115-125. doi: 10.1111/neup.12938. Epub 2023 Jul 31.

Development of mobile compatible software for cognitive-communication disorder in individuals with Alzheimer's disease

Parlak MM, Köse A, Güç M, Munis ÖB.

Int J Lang Commun Disord. 2024 Jan-Feb;59(1):234-254. doi: 10.1111/1460-6984.12941. Epub 2023 Aug 1.

Ginsenoside Rg1, lights up the way for the potential prevention of Alzheimer's disease due to its therapeutic effects on the drug-controllable risk factors of Alzheimer's disease

Wu JJ, Zhang L, Liu D, Xia J, Yang Y, Tang F, Chen L, Ao H, Peng C.

J Ethnopharmacol. 2024 Jan 10;318(Pt B):116955. doi: 10.1016/j.jep.2023.116955. Epub 2023 Aug 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias